Dementia diagnosis is associated with changes in antidiabetic drug prescription: an open-cohort study of ~130,000 Swedish subjects over 14 years
There is also growing interest in whether these medications have tissue-level anti-inflammatory effects beyond weight loss alone
The 2026 Standards of Care by the American Diabetes Association (ADA) recommend them for adults with type 2 diabetes who also have obesity or overweight, atherosclerotic cardiovascular disease, heart failure, chronic kidney disease or metabolic-associated steatotic liver disease [4]
To address this, an alternate design could have been to test consecutive day dosing and then have a washout period and then test the alternate day dosing
This medicine is characterized by minimal reported unfavorable effects
Since the cost to manufacture GLP-1s is modest, higher utilization could lead to better health for the population and more profit for the pharmaceutical companies